Richard Paul Russo Jr. - 14 Oct 2021 Form 4 Insider Report for Bionik Laboratories Corp.

Role
CFO and Interim CEO
Signature
/s/ Rich Russo
Issuer symbol
BNKL on OTC
Transactions as of
14 Oct 2021
Net transactions value
$0
Form type
4
Filing time
15 Oct 2021, 17:02:19 UTC
Next filing
13 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNKL Employee Stock Option (right to buy) Award $0 +80,000 $0.000000 80,000 14 Oct 2021 Common Stock, par value $0.001 80,000 $2.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the options vest as follows: 10,000 on the date of grant; 10,000 on October 14, 2022; 10,000 on October 14, 2023; and 10,000 on October 14, 2024. The other 50% of the options vest based on performance goals to be set for each of the first three years after grant.